In an indication with few treatment options for patients who are running out of time, Replimune Group Inc. revealed positive top-line results of its lead candidate, RP-1 (vusolimogene oderparepvec), in anti-PD-1-failed melanoma. Data from the phase I/II Ignyte study of RP-1 plus Opdivo (nivolumab, Bristol Myers Squibb Co.) showed the treatment hit the primary endpoint with a 12-month overall response rate of 33.6% and a median duration of response of more than 35 months.
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CEO Sushil Patel sold 20,194 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $130,655.18. Following the completion of the sale, the chief executive officer now owns […]
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CEO Sushil Patel sold 20,194 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $130,655.18. Following the completion of the sale, the chief executive officer now owns 212,014 shares […]
Replimune Group, Inc. (NASDAQ:REPL – Free Report) – Research analysts at Leerink Partnrs dropped their Q1 2025 earnings estimates for shares of Replimune Group in a research report issued on Thursday, May 16th. Leerink Partnrs analyst J. Chang now anticipates that the company will earn ($0.85) per share for the quarter, down from their previous […]
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) COO Colin Love sold 17,615 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total transaction of $113,969.05. Following the transaction, the chief operating officer now directly owns 777,345 shares in the company, […]